FOLH1 and prostate adenocarcinoma: 177Lu-vipivotide tetraxetan ([177Lu]Lu-PSMA-617) is used in the treatment of prostate-specific membrane antigen–expressing metastatic castration-resistant prostate adenocarcinoma.